跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IXIARO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
IXIARO
Authorized
STANDARD
IXIARO
Valneva Austria GmbH
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
46827d2dd63b16d0
Company
Valneva Austria GmbH
Type
Standard
Approval Details
Approval Id
46827d2dd63b16d0
Drug Approval Canada Name
IXIARO
Product Name
IXIARO
Status
Marketed
Status Date
2013-10-09
Original Market Date
2009-12-29
Din
02333279
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BA02 ENCEPHALITIS, JAPANESE, INACTIVATED, WHOLE VIRUS
Atc Name
j 07 ba 02
Aig Number
0152652001
Company Name
Valneva Austria GmbH
Company Address
Campus Vienna Biocenter 3, Vienna, Wien, Austria, 1030
Company Detail Path
/organization/valneva-austria-gmbh
Company Information
Pharmaceutical Company Name
Valneva Austria GmbH
Name Zh
瓦尔尼瓦奥地利有限责任公司
Country Name
Austria
Province Name
wien,country_at
City Name
wien,wien,country_at
Address
Campus Vienna Biocenter 3
Website
http://www.valneva.at
Active Ingredients
INACT.JAPANESE ENCEPHAL VIRUS(ATTENUAT. STRAIN SA14-14-2 PRODUCED IN VERO CELLS)
6 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
46827d2dd63b16d0
Type
Standard
Back to Health Canada Approvals